Drugs · Entity Annotation Prototype (beta)

3articles mentioning drugs

28drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: DZP ×

DZP

This drug is selected. Its supporting articles are shown below.

DZP3

Articles mentioning DZP

3 articles · page 1 of 1

PT4:04 Achievement of low disease activity and remission in patients with SLE treated with dapirolizumab pegol: updated 48-week analyses from a phase 3 trial including lower glucocorticoid dose criteria

lupusscimed · abstract · 2026-03-01 · 10 matching annotations

93.9%

dapirolizumab pegol DZP prednisone PBO SLE Lupus NCT04294667

… outcomes, from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP is a novel CD40L inhibitor with broad modulatory effe…

PO:13:336 Improvement of fatigue, musculoskeletal pain, morning stiffness and health-related quality of life in patients with SLE treated with dapirolizumab pegol: 48-week results from a phase 3 trial

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

84.1%

Dapirolizumab pegol DZP prednisone SLE SLE-specific Lupus

… including fatigue, musculoskeletal pain and morning stiffness. Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects …

S15:02 Dapirolizumab pegol and flare reduction in patients with SLE in a 48-week phase 3 trial: an updated post hoc analysis of alternative definitions of flares that reflect clinical practice

lupusscimed · abstract · 2026-03-01 · 9 matching annotations

93.0%

dapirolizumab pegol DZP prednisone PBO BILAG-2004

…using data from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP, a novel CD40L inhibitor, consists of a polyethylene …